Soy isoflavones for prevention of menopausal bone loss and vasomotor symptoms

Archives of Internal Medicine

Volumn 171, Issue 15, 2011, Pages 1369-1370

  Newton, Katherine M ^a   Grady, Deborah ^b,c  

^a CENTER FOR HEALTH STUDIES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAIDZEIN; EQUOL; ISOFLAVONE;

ADULT; BONE DENSITY; CONTROLLED STUDY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FRACTURE; HIP; HOT FLUSH; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; NOTE; OSTEOLYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; VASOMOTOR DISORDER;

EID: 80051609355     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2011.331     Document Type: Note

References (12)

1. Grady D. Management of menopausal symptoms.NEngl J Med. 2006;355:2338- 2347.
2. Ahlborg HG, Johnell O, Nilsson BE, Jeppson S, Rannevik G, Karlsson MK. Bone loss in relation to menopause: a prospective study during 16 years. Bone. 2001;28(3):327-331. (Pubitemid 32194419)
3. Anderson GL, Limacher M, Assaf AR, et al Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712. (Pubitemid 38489892)
4. Shumaker SA, Legault C, Kuller L, et al Women's Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004;291(24):2947-2958. (Pubitemid 38802684)
5. Rossouw JE, Anderson GL, Prentice RL, et al Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. (Pubitemid 34761611)
6. Shumaker SA, Legault C, Rapp SR, et al WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289(20):2651-2662. (Pubitemid 37430136)
7. Levis S, Strickman-Stein N, Ganjei-Azar P, Xu P, Doerge DR, Krischer J. Soy isoflavones in the prevention of menopausal bone loss and menopausal symptoms: a randomized, double-blind trial. Arch Intern Med. 2011;171(15):1363-1369.
8. Ricci E, Cipriani S, Chiaffarino F, Malvezzi M, Parazzini F. Soy isoflavones and bone mineral density in perimenopausal and postmenopausal Western women: a systematic review and meta-analysis of randomized controlled trials. J Womens Health (Larchmt). 2010;19(9):1609-1617.
9. Liu J, Ho SC, Su Y-X, Chen W-Q, Zhang C-X, Chen Y-M. Effect of long-term intervention of soy isoflavones on bone mineral density in women: a meta-analysis of randomized controlled trials. Bone. 2009;44(5):948-953.
10. Taku K, Melby MK, Kurzer MS, Mizuno S, Watanabe S, Ishimi Y. Effects of soy isoflavone supplements on bone turnover markers in menopausal women: systematic review and meta-analysis of randomized controlled trials. Bone. 2010;47(2):413-423.
11. Lampe JW. Is equol the key to the efficacy of soy foods? Am J Clin Nutr. 2009;89:16645-16675.
12. Bolaños R, Del Castillo A, Francia J. Soy isoflavones versus placebo in the treatment of climacteric vasomotor symptoms: systematic review and meta-analysis. Menopause. 2010;17(3):660-666.